Please assess the completion status of the following clinical trial:

Trial Title: A Multicentre Trial to Determine the Efficacy and Safety of Milnacipran in the Treatment of Fibromyalgia Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patient with a diagnosis of fibromyalgia according to the 1990 American College of Rheumatology (ACR) criteria~Exclusion Criteria:~* psychiatric illness~* depression of generalised anxiety disorder~* suicidal risk~* substance abuse~* active cardiac disease~* pulmonary dysfunction~* liver disease~* renal impairment~* autoimmune disease~* chronic inflammatory rheumatoid disease~* current systemic infection~* epileptic~* active cancer~* sleep apnea~* active peptic ulcer~* inflammatory bowel disease~* unstable endocrine disease~* for men : prostatic enlargement of genito-urinary disorders~* for women : pregnancy or breast feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- Minalcipran (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).